All In Biotech

Drug Trial Radar · NCT07858734

Postsurgical Analgesia After Unilateral Bunionectomy

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of AMT-143 for Postsurgical Analgesia After Unilateral Bunionectomy

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Nov 1, 2026

Primary completion

Apr 15, 2027

Study completion Jun 15, 2027

Sponsor

Lead sponsor
AmacaThera Inc.Industry
Sponsor type
Industry
First posted
Oct 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Supportive care
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is designed to evaluate the safety, efficacy, and pharmacokinetics (PK) of two doses of AMT-143 in participants after unilateral bunionectomy.

Conditions

  • Bunionectomy
  • Bunion

Interventions

  • AMT-143Drug

    Group 1 will receive AMT-143 containing 354 mg ropivacaine.

  • AMT-143Drug

    Group 2 will receive AMT-143 containing 707 mg ropivacaine.

  • Saline (NaCl 0,9 %) (placebo)Other

    Group 3 will receive 2.00 mL Placebo \[sodium chloride (NaCl) 0.9%\].

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability of AMT-143Time frame: From surgery to Day 28 follow-up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Diex Reserche

    Sherbrooke, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.